1. Home
  2. ACCL vs NXTC Comparison

ACCL vs NXTC Comparison

Compare ACCL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACCL

Acco Group Holdings Limited Ordinary Shares

N/A

Current Price

$3.10

Market Cap

57.8M

ML Signal

N/A

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$13.34

Market Cap

46.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACCL
NXTC
Founded
2009
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
57.8M
46.6M
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
ACCL
NXTC
Price
$3.10
$13.34
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
82.0K
37.2K
Earning Date
02-20-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
2.91
N/A
EPS
0.08
N/A
Revenue
$4,888,824.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$35.11
N/A
Revenue Growth
11.91
N/A
52 Week Low
$2.10
$2.69
52 Week High
$5.00
$15.74

Technical Indicators

Market Signals
Indicator
ACCL
NXTC
Relative Strength Index (RSI) N/A 57.16
Support Level N/A $12.79
Resistance Level N/A $14.65
Average True Range (ATR) 0.00 0.99
MACD 0.00 0.10
Stochastic Oscillator 0.00 65.18

Price Performance

Historical Comparison
ACCL
NXTC

About ACCL Acco Group Holdings Limited Ordinary Shares

Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: